EPS · actual vs est
Revenue · actual vs est
Summary
Generated 2026-03-31
Management highlights
Andrew mentioned that the global phase three clinical trial Native 3 completed enrollment in April 2025 and expects top - line readout in Q4 2026. In Q4 2025, Inventiva sold its global rights to Oda Parcel to Biasil. The company strengthened its leadership team. Jason updated on lanofibrinor's mechanism of action, development pathway, and the details of Native 3 trial
Segment performance
Not explicitly detailed in the provided transcript regarding absolute financial performance and revenue contribution % for each product segment
Guidance
Anticipates top - line readout of Native 3 trial in Q4 2026. Estimates cash runway extends to mid - Q1 2027 and mid - Q3 2027 assuming full exercise of Tranche 3 warrants
Risks
Refer to SEC and AMF filings for discussion of associated risks
Q&A highlights
Q: Can you update us on how the performance of the trial has been in terms of dropouts...
A: Seamus Fernandez's questions about trial dropouts, dose performance, and market interest were answered by Andrew and Jason.
Q: Native 3 is a very large data set...
A: Yasmin Rahimi's questions about biopsy sample analysis and safety monitoring were answered by Andrew and Jason.
Q: Drill down a little bit more upon final powering...
A: Ritu Barao's questions about trial powering and F3 diabetic population were answered by Jason.
Q: Follow up on that F4 population...
A: Thomas Smith's questions about F4 population were answered by Jason.
Q: On weight gain...
A: Michael Yee's questions about weight gain were answered by Jason.
Q: Follow - up to Richie's question...
A: Ellie Merla's questions about competitive data and undiagnosed MASH were answered by Andrew.
Q: Regarding the confirmatory trial...
A: Lucy Codrington's questions about confirmatory trial were answered by Jason.
Q: Around the use of background GLP - 1s...
A: Annabel Samimi's questions about GLP - 1 use and AIM - MASH tool were answered by Jason.
Q: Remind us of lanofibrinors FC and F2 versus F3 patients...
A: Rami Katsouda's questions about lanofibrinor in F2 and F3 patients were answered by Jason.
Q: Looking ahead a little bit in terms of the MASH guidelines...
A: Anna's questions about MASH guidelines and cash were answered by Andrew.
Q: Could you elaborate on your regulatory and commercial infrastructure...
A: Priscilla Hernandez's question about regulatory and commercial infrastructure was answered
Key numbers
Reported versus consensus
Earnings calendar feed
| Metric | Reported | Consensus | Delta | Prior year |
|---|---|---|---|---|
| EPS | — | $-0.28 | — | — |
| Revenue | — | $5.6M | — | — |
Transcript
March 31, 2026Full transcript unavailable for redistribution
The structured summary above covers the available call sections. Full transcript text is not included on this page.
Continue exploring
Prior quarters
This page presents the stored structured earnings-call summary and deterministic earnings calendar values. How this is generated. For informational purposes only; not investment advice.